A

Agios Pharmaceuticals
D

AGIO

36.020
USD
0.65
(1.82%)
مغلق
حجم التداول
11,913
الربح لكل سهم
-7
العائد الربحي
-
P/E
3
حجم السوق
2,086,105,468
أصول ذات صلة
C
CRSP
0.455
(0.88%)
52.120 USD
E
EDIT
0.02000
(0.78%)
2.57000 USD
N
NTLA
-0.020
(-0.19%)
10.710 USD
Q
QURE
0.080
(0.56%)
14.400 USD
R
RARE
0.480
(1.21%)
40.000 USD
S
SGMO
0.00200
(0.38%)
0.53200 USD
S
SRPT
0.010
(0.06%)
18.200 USD
المزيد
الأخبار المقالات

العنوان: Agios Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.